LOS ANGELES--(BUSINESS WIRE)--Glancy Binkow & Goldberg LLP announces that a class action lawsuit has been filed in the United States District Court for the District of Massachusetts on behalf of a class (the “Class”) comprising all purchasers of the securities of InVivo Therapeutics Holdings Corp. (“InVivo” or the “Company”) (OTC:NVIV) between April 5, 2013 and August 26, 2013, inclusive (the “Class Period”).
Please contact Casey Sadler, Esquire, at (888) 773-9224 or (310) 201-9150, or at shareholders@glancylaw.com to discuss this matter. If you inquire by email, please include your mailing address, telephone number and number of shares purchased.
InVivo develops biomaterial technologies for the treatment of spinal cord injuries and hydrogels for therapeutics delivery. The Complaint alleges that defendants made false and/or misleading statements and failed to disclose material adverse facts about the Company’s business, operations and prospects. Specifically, defendants misrepresented and/or failed to disclose that the Company’s clinical study for its biopolymer scaffolding to treat acute spinal cord injuries would not be completed with all data submitted to the FDA by the end of 2014, and the Company did not anticipate completing this clinical study until late 2015. As a result, the Company’s statements about its clinical study timeline for biopolymer scaffolding to treat acute spinal cord injuries were materially false and misleading and/or lacked a reasonable basis.
If you purchased InVivo shares between April 5, 2013 and August 26, 2013, you may move the court to serve as lead plaintiff, if you meet certain legal requirements. To be a member of the Class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Casey Sadler, Esquire, of Glancy Binkow & Goldberg LLP, 1925 Century Park East, Suite 2100, Los Angeles, California 90067, by toll-free telephone at (888) 773-9224 or by telephone at (310) 201-9150, by e-mail to shareholders@glancylaw.com, or visit our website at http://www.glancylaw.com. If you inquire by email, please include your mailing address, telephone number and number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
